December 2026 Options Now Available For Encompass Health (EHC)

Encompass Health (EHC) is trading at $106.16; a $105 put is bidding $7.00 (implying a net effective purchase basis of $98 if sold-to-open) and is ~1% OTM with a 61% probability of expiring worthless, yielding 6.67% (6.76% annualized) on the cash commitment. On the call side, a $115 call bids $7.50 and would produce a 15.39% total return if stock is called at the December 2026 expiration (strike ~8% OTM) with a 52% chance of expiring worthless and a 7.06% (7.16% annualized) YieldBoost if it does. Implied volatility is ~27–28% (put 27%, call 28%) and trailing 12‑month volatility is ~27%; Stock Options Channel is tracking odds and contract histories for these strategies.

Analysis

Market structure: Option sellers and yield-seeking retail/institutional investors are the immediate winners — selling the EHC Dec-2026 $105 put nets $7 (effective buy at $98) and covered-call writers capture $7.50 on a $115 cap (15.4% gross to strike). Because implied vol (27–28%) essentially equals realized vol (27%), these premiums reflect yield demand more than a volatility risk premium; liquidity risk is modest but concentrated assignment could create episodic selling pressure.

Risk assessment: Near-term (days–weeks) the primary risks are IV spikes and headline-driven flows; the quoted odds (put expires worthless 61%, call 52%) imply modest directional bias but not comfort against a >10% downside. Medium-term (months) tail risks include CMS/Medicare reimbursement changes, occupancy/litigation shocks or M&A that could cut EBITDA by >5–10%; long-term (years) secular reimbursement pressure could compress multiples. Hidden dependency: large-scale option assignments could force shares into a retail base and increase float-driven volatility.

Trade implications: Direct plays: sell-to-open EHC Dec-2026 105 puts to create a 2–3% sized prospective long at $98 (stop/hedge if EHC < $90 or IV > 32%). Buy-write alternative: buy EHC up to 3% weight and sell Dec-2026 115 calls to harvest ~7.1% annualized YieldBoost (accept assignment at $115). If downside protection desired, convert to a collar by buying a Dec-2026 95 put before assignment risk becomes real.

Contrarian angles: Consensus overlooks that IV≈realized — this is a pure income trade, not a volatility arbitrage; sellers are being compensated for time decay, not for unknown regulatory tail risk. The trade may be underpricing a >10% reimbursement shock; historically (post-2015 Medicare adjustments) post-acute providers saw 20–30% multiple re-ratings. If you believe reimbursement risk is understated, avoid naked put sells and prefer tight collars or buy-writes with protective puts.

Key Decisions for Investors

• Sell-to-open EHC Dec-2026 $105 put for ~$7 to establish a 2–3% portfolio position (effective cost basis $98). Risk-manage: buy to close if EHC < $90 or if IV rises >5 pts to >32% (loss limit ~8–10%).
• If comfortable owning stock, initiate a buy-write: buy EHC up to 3% weight at market (~$106) and sell Dec-2026 $115 call for ~$7.50; allow assignment at $115 (15.4% pre-fees) or buy back calls if stock >$120.
• If worried about policy/regulatory tail risk, implement a collar upon assignment: long EHC and sell $105 put / buy Dec-2026 $95 put (or equivalent) to cap downside; avoid collar if put protection cost >$3 (reevaluate).
• Reallocate 2–4% from high-volatility biotech into healthcare services exposure (EHC via covered income trades). Monitor CMS proposed rule changes and EHC quarterly results within the next 30–60 days; if CMS changes imply >2% estimated revenue hit, reduce EHC exposure to zero.